The recent meta-analysis with the pooled population of 8474 patients (DAPA-HF and EMPEROR-Reduced population) showed that treatment with an SGLT2-i was associated with a significant reduction in cardiovascular death (pooled hazard ratio of 0.86) and re-hospitalization due to heart failure complications as well as improvements in renal function [19]. The gene discussed is SLC5A2; the disease is heart failure.